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A qualitative exploration of early
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technologies
Iben Fasterholdt1,3* , Anne Lee1, Kristian Kidholm1,3, Knud Bonnet Yderstræde2 and Kjeld Møller Pedersen3
Abstract
Background: Hospitals increasingly make decisions about early development of and investment in innovative
medical technologies (IMTs), but at present often without an early assessment of their potential to ensure selection of
the most promising candidates for further development. This paper explores how early assessment is carried out in
different health organisations and then discusses relevant learning points for hospitals.
Methods: A qualitative study design with a structured interview guide covering four themes was used. Content
analyses of interview notes were performed covering four predetermined themes: context, basis for decision-
making, process and structure, and perceptions. A fifth theme, handling cognitive bias, was identified during
data analysis.
Results: A total of 11 organisations participated; eight from the private health industry and three public hospitals.
The interviews identified four areas in which early assessment is performed in similar manner across the studied
organisations and four areas where differences exist between public hospitals and private organisations. Public
hospitals indicate a lower degree of formalised early assessment and less satisfaction with how early assessment
is performed, compared to private organisations. Based on the above findings, two learning points may carry
promise for hospitals. First, having dedicated prioritising committees for IMTs making stop/go decisions. This
committee is separate from the IMT development processes and involved staff. Secondly, the committee should
base decisions on a transparent early assessment decision-support tool, which include a broad set of domains, is
iterative, describes uncertainty, and minimise cognitive biases.
Conclusions: Similarities and differences in the way early assessment is done in different health organisations
were identified. These findings suggest promising learning points for the development of an early assessment
model for hospitals.
Keywords: Early assessment, Health technology assessment, Interview, Innovation
Background
As part of the increasing technology development and
digitalisation of the healthcare systems, hospitals estab-
lish centers for innovation [1, 2] and engage in design-
ing, developing, and testing innovative medical
technologies (IMTs). IMT in general include medical
devices, medical/surgical procedures, processes of care,
and clinical health information systems, e.g. an app for
discharge early postnatally [3], an automatized medical
ultrasound examination and interpretation robot [4],
telemedicine training after hospitalisation with severe
chronic obstructive pulmonary disease [5], and 3D
camera for ulcer treatment and care [6].
Traditionally, the process of development of IMTs/
pharmaceuticals takes place in a pharmaceutical, medical
device or IT industry setting. After industry product
development and testing hospitals make a purchasing
decision, i.e. decide to start large-scale clinical tests or
adopt the IMT. The agreement between the two
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stakeholders, industry and hospital, hence was: “hospitals
buying” and “industry developing and delivering” [7].
However, we argue that this division of labor is gradually
changing because of a national and international focus
on promoting public-private partnerships [8], and the
aforementioned creation of dedicated innovation units
in large hospitals. Consequently, hospitals join the
process earlier and are increasingly involved in develop-
ing IMTs, either internally or by working in close collab-
oration with industry.
IMTs often require interdepartmental cooperation,
considerable costs and large investments, and significant
modification in features, design, or properties before
widespread clinical use or adoption. Therefore, early
assessment of early stage IMTs is needed and may pro-
vide hospitals with the following three benefits: 1) The
ability to discriminate potentially promising IMTs from
less advantageous ones early in the process, and thus
avoiding misallocating public resources [9], 2) Early
influence on an IMT’s value proposition [10], and 3) A
system that safeguards against “pro-innovation bias”
[11], i.e. the perception that any innovation (IMT) will
lead to increased performance, often due to unrealistic
assumptions and optimism bias [12].
If formal evaluation of IMT is performed, it is often con-
ducted late in the developmental process [13, 14] using
traditional approaches like Health Technology Assess-
ments (HTA), hospital-based HTAs, cost-effectiveness
analyses, or clinical trials. Using a popular scale for asses-
sing the maturity level of a particular technology this
corresponds to level 7 to 9 in Fig. 1 (where 1 is the lowest
maturity and 9 is the highest). In contrast, early assess-
ment of IMTs normally takes place between level 3 to 7 in
terms of technological maturity [15], Fig. 1.
However, assessment of investments in IMTs early in
the development process is different from the task of
assessing mature technologies at later stages deciding
whether adoption is warranted. Data from early phases
will by nature be limited and a high level of uncertainty
concerning clinical, patient, economic, and organisa-
tional effect exists. Thus, early assessment is based on
feasibility, pilot, demonstration, or initial effect data gen-
erated for the IMT and exclude large-scale testing or
traditional clinical research.
Currently, the best approach for early assessment of the
potential of IMTs in hospitals is unknown. Thus, there is a
need to develop a model for early assessment in hospitals.
This study provides the first, qualitative step in this en-
deavour by exploring how early assessment of IMTs is per-
formed and perceived in different health organisations and
subsequently discuss relevant learning points for hospitals.
Methods
A qualitative exploratory study was used to investigate
how early assessment of expected potential/value of
innovation projects is performed in three sectors: private
pharmaceutical and medical device industry and in pub-
lic hospitals. By choosing an exploratory research design
we basically explore the research question, leaving room
for further conclusive research aimed at providing
Fig. 1 Defining early with Technology Readiness Levels (TRL) based on early NASA model
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(more) final findings [16]. Data collection took place
from August 2014 – June 2015. An interview guide was
developed and eleven interviews were conducted: ten
face to face and one as a telephone interview, lasting
one to two hours.
A mix of convenience and the purposive sampling pro-
cedure of maximum variation [17] was used to select
companies and hospitals. Participants for interviews
were identified through the authors’ networks according
to three pre-specified selection criteria: probable experi-
ence with early assessment, sector, and size of organisa-
tion. Thus, the study population consisted of experts
and professionals from large device and pharmaceutical
companies and university hospitals, working in an R&D
or innovation unit having experience with early assess-
ments of IMTs. Apart from one case, the interviewer
(IF) had no prior relationship with the participants.
Recruiting new organisations was an iterative process
and continued until the themes seemed exhausted in the
way that new information was minor [18].
The developmental process in pharmaceutical and med-
ical devices is very competitive and highly sensitive to
business interests. In the literature it is mentioned that in-
ternal strategic decisions, i.e. early assessments, are rarely
published and take place behind closed company doors
[19, 20]. Hence, due to confidentiality concerns it was de-
cided that the interviews were not recorded knowing that
from a methodological point of view it would be a weak-
ness but considered necessary to gain access to key per-
sons. Instead, detailed notes were taken during the
interviews. At the start of each interview, participants
were informed about the objective of the study and that
their answers were anonymous.
Development of the interview guide
As advocated by Miles, Huberman and Saldana [21] ini-
tially a rudimentary conceptual framework was built to
orient the study [see Additional file 1], and key factors
relevant to early assessment were described resulting in
the four research themes: context, basis for decision
making, process and structure, and perceptions.
This process included a preparatory literature search
later published as a review by our group [22]. From this
work, a toolkit for the identification and assessment of
new and emerging health technologies [23] motivated
questions on frequency of updates of IMT, time horizon,
templates, and questions on satisfaction with the
process. Further, a planned study of early economic
evaluation of emerging health technologies [24] inspired
the questions on the basis for decision making, including
the importance of risk/uncertainty. Also, valuable inputs
for the interview guide were solicited through discus-
sions with a diverse and skilled supervisor team includ-
ing two health economists and one medical doctor.
Based on this an interview guide was developed and
then subsequently piloted by a health technology assess-
ment consultant outside the author team. The questions
were generally well understood and reductions and some
minor changes to reflect more open questions were in-
cluded. Table 1 shows the four predetermined research
themes and a rough sketch of related questions. The
complete interview guide and details about its develop-
ment are published elsewhere [25].
Data analysis
Qualitative content analysis was used to investigate both
the obvious content and underlying themes and meanings
Table 1 Overview of research themes and questions regarding early assessment
Theme Questions
1) Context What is the time horizon in the developmental process?
How many technologies/ideas do you evaluate in one year – rough estimate of the size of your
portfolio of projects?
2) Foundation/basis for decision making Is there an approach/template for early assessments? Do you use a fixed/systematic procedure?
What are the dimensions/inputs in the early assessment - Which components are used?
• Do you use qualitative data/information?
• Do you use quantitative data/information?
• Is there an economic calculation (even simple) in the pilot phase?
• Are expected clinical effects included early – for example mortality, amputations, admissions?
Do you perform risk/uncertainty assessments?
3) Process and structure of early assessment Which phases are used in the developmental process?
Are there stop/go decisions in the process of development – what are they based on?
Do you update your assessments regularly – how often?
Who decides whether to continue an innovation - who makes the go/no-go decision?
How do you decide which effects to include?
Success ratea: Which proportion of projects/ideas survives the “pilot phase” and achieves routine
use or commercialisation?
4) Perceptions Relevance and satisfaction with the used method?
What are the pros? And what are the cons (wish list)?
aDefinition of success rate: The proportion of an organisation’s R&D product portfolio that “survives” the early phases in the developmental process and becomes
a “success”. While success in the public sector is defined by the product achieving routine use, in the private sector the product must be commercialised or
launched on the market to be termed a success
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of the phenomena studied [21]. Conceptual (deductive)
coding in the form of codes from the four predetermined
themes was used and to a minor degree supplemented by
(inductive) data-driven coding identifying a new theme
[21, 26]. The following components were present in the
data analysis: data reduction, data display and interpret-
ation/conclusion drawing and validation, forming a cyc-
lical process moving between the components [21].
Through this process, an extended text was reduced and
ordered to allow careful comparisons, detection of differ-
ences and noting of patterns and themes [21, 26], as de-
scribed in the following three stages.
At stage 1 an initial data reduction took place, captur-
ing the essence of the interview based on notes taken
during interviews. Each interview was then assigned a
name in arbitrary order from H1-H3 for public hospi-
tals and PI-P8 for private organisations. In the second
stage a descriptive matrix was designed to display data
[21] and this essential construct is visualized in the left
part of Fig. 2.
A sector and variable-ordered matrix was constructed
for each of the four themes and with the organisations
(H1 to H3 and P1 to P8) as rows and research questions
as the columns. Hence, the initial matrix was built on the
themes and research questions chosen by the authors
(Table 1). Next, reading through the interview data, one
interview at a time, IF placed individual pieces of data in
the corresponding matrix-cell until all data were aggre-
gated according to the four themes and categorised ac-
cording to the sub-questions. During this process and as
some data did not correspond to the predefined themes a
new theme labelled cognitive bias and a fifth matrix was
constructed. Cognitive biases are described as ‘systematic
pattern of deviation from norm or rationality in judgment,
whereby inferences about other people and situations may
be drawn in an illogical fashion’ [12].
In stage 3 the content of the theme matrices were
investigated. Each matrix was read vertically first, i.e.
column-wise (for specific questions), giving a picture of
the answers to each question across different organisa-
tions. Next, horizontal reading gave a picture of each orga-
nisation’s answers across all questions in a theme. This
method provided useful means for assessing patterns, i.e.
similarities and differences between organisations, be-
tween the three sectors (and eventual between public and
private). At this stage a further data/meaning condensa-
tion took place and a “next-step matrix” [21] was con-
structed. This is illustrated in the right part of Fig. 2. Also,
a validation of the analysis and conclusions on the basis of
the matrices [21] were performed through repeated dis-
cussions with a researcher (AL) having extensive qualita-
tive expertise and who had not been involved in the
development of the interview guide or the conducting of
the interviews. Any disagreement in interpretation of data
was discussed until a consensus was reached. Lastly, all
authors of the article discussed the results of the analysis.
In the presentation of the results quotes were trans-
lated from Danish to English by the authors. A cut-off
was used so that least two statements from different
organisations were needed to provide support for a given
opinion/reflection before reported, and when more than
half of the answers support a given opinion, the term
majority is used. During some interviews, a number of
questions were left out due to lack of relevance or low
priority given the variation in available time for the
interview. Thus, this article was based on questions that
were answered in most interviews while a few questions
with few reflections were not included in the analysis.
Fig. 2 Data display and data and meaning condensation for theme 3, question 1. Note: Left part: Raw data, right part: Reduced data
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Results
In the following, the results of the analysis are presented
according to the four previously outlined themes. How-
ever, due to overlap between themes, some questions are
included under a different theme than in the interview
guide (Table 1). Explicit excerpts from the interview
notes supporting the results below are presented in
[Additional file 1]. Standard project management ter-
minology and tools are assumed known to readers and
definitions and examples of templates for management
tools might be found in any project management litera-
ture, e.g. in Olsson and Ahrengot [27].
Theme 1: Context
A total of 25 individuals representing eleven Danish
organisations participated in the interviews. All invited
organisations chose to participate; three organisations
(H1,H2,H3) representing the public hospitals; two som-
atic hospitals and one psychiatric hospital. Eight organi-
sations represented the private sector: five organisations
from the pharmaceutical industry (P1,P3,P4,P5,P6) and
three (P2,P7,P8) from the medical device industry.
In the private sector, most respondents were from
senior management and interviews were almost exclu-
sively performed with only one individual. In the public
healthcare sector, interviews included on average four
individuals; the majority being junior staff with limited
experience. The number of R&D projects (IMTs) in the
pipeline varied greatly at the time of interview and based
on answers from eight organisations the range was 20 to
350. Based on six organisations the time horizon for
developing a product ready for launch in the market or
adoption for routine use ranged from 10 years to
develop a product down to 2 weeks to develop an app.
Theme 2: Foundation or basis for decision-making
Various criteria or domains are used to make stop/go
decisions and organisations state that they use a mix of
quantitative and qualitative methods for assessment. The
following five main criteria are stressed:
 Strategic fit/misfit vis-à-vis the strategic aims of the
organisation (H1,P3,P4,P7)
 Clinical effects or technological aspects, including
target product profile (P3,H3,P4,P5,P6,P7) or
competition and pro/cons of competing technologies
(P2,P3,H3,P6,P7,P8)
 Patient or customer perspective (H1,P2,H3)
 Organisational issues including staff, education
(H1,H3,P7)
 Business cases or cost analysis (H1,H2,H3,P1,P2,P3,
P4,P5,P6,P7,P8), market analysis or size of target
group (H1, H3,P1,P3, P4,P5,P6,P7), needs
assessment (P5,P7,P8), patents (P3,P5)
All organisations indicate the use of risk or uncer-
tainty assessment, and traditional project management
tools for risk assessment, including probability of an
event multiplied by impact (H2,P1,P3,P7), were popu-
lar. However, the degree to which the organisations
believe risk/uncertainty assessment to be important
seems to vary from low in the public sector (H1,H2)
to very high in most private organisations
(P1,P3,P6,P7). Example of other tools used in risk/un-
certainty assessment and attitudes towards risk assess-
ment are presented in [Additional file 1].
Theme 3: Process and structure of early assessment
Most organisations are very structured in their assess-
ment process. The majority indicate having an approach
or template for doing early assessments
(H1,P1,P2,P3,P4,P5,P6,P7,P8) - two organisations have
not (H2,H3). When asked about how systematic their
early assessment approach is, answers range from very
systematic (P1,P3,P5,P6,P7,P8) to not so systematic
(H1,H2,P2,H3,P4).
How the interviewed organisations decide which attri-
butes or effects to include range from very ad-hoc
(H1,H2,P2) to more structured and systematic
approaches (P1,P3,P4,P5,P6,P7). Some mention having a
tool or template as a point of departure (H1,P5,P7). P2
note that they “assess from a case-to-case basis”. An
example of a more structured approach is P3, who note
that “much is decided by authorities, guidelines”.
Phases
The use of a phase model in the developmental process
is prevalent and often standard models are used, e.g.
tools from project management (tracking milestones,
PRINCE2 model), proof of concept models, stage-gate
models, or the phase 1–4 terminology used in clinical
research when developing pharmaceuticals. Two public
organisations (H2,H3) indicated no use of phases in the
developmental process. The remaining organisations all
use a phase model ranging from very detailed models
(H1,P1,P3) to more simple (few phases) or they use
standard project management or innovation models like
the “Technology Readiness Levels” model, cf. Figure 1
(P2,P4,P5,P6,P7,P8).
Updating and learning from past experiences
The majority update their assessments regularly over the
development phases, while it varies how often and how
stringently, but the idea of continuously learning is
prevalent. Two public hospitals (H2,H3) do not mention
updating their assessments regularly – the rest say that
they do. Five private organisations (P3,P5,P6,P7,P8)
explicitly mention time intervals for updates ranging
from monthly, to every 6 months, to once a year. Some
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private organisations actively use past information to
qualify the assessments of new technologies (P3,P4,P6).
Examples are historical probabilities of success in assess-
ment of new IMTs, cost estimates, probability for phase
transition, etc.
The use of a formal go/no-go committee
The majority of organisations (H1,P1,P2,P3,P4,P5,P6,P7,P8)
have formalised stop/go decisions in the process of devel-
opment, e.g. stop/go is made (almost) entirely in a formal
decision committee or board dedicated to priority setting
and making go/no go decisions. However, two public hospi-
tals (H2,H3) have no formalised stop/go decisions in the
process of development but have what they call “organisa-
tional” stop/go. Note on H2: “No – but organisational stop/
go, i.e. if there is no ownership in a department, develop-
ment can be brought to an end. There are no systematics,
however. If a department has access to financing, they can
just continue the process”. The innovation unit or project
staff to some degree decide go/no-go in the three public
hospitals (H1,H2,H3) – and if they do not decide “organisa-
tional” stop/go comes into play. In contrast to this organisa-
tion P1 has detailed descriptions of all meeting activities in
relation to the product development, e.g. aim, standard
agenda, frequency, participants, and their roles and respon-
sibilities in/before the meeting, etc. In the private sector,
stop/go decisions are made almost entirely in formal com-
mittees or boards dedicated to prioritising and often con-
sisting of senior management or Chief Executive Officer
level (depending on the magnitude of the decision). Exam-
ples are: Portfolio board, product review committee,
pipeline-forum, and product priority group.
Success rate in product development
Figure 3 displays the self-reported success rates (defin-
ition provided in method section) of ten organisations.
On average, only 10% of the IMTs end up being a suc-
cess. In the public sector, the figure is 15%, while the pri-
vate sector on average reports a success rate of 8%. The
success rates ranged from 1 to 22% indicating consider-
able variation, especially intra-sector variation in the pri-
vate sector ranging from very low rates around 1–5% to
as high as 22%.
Theme 4: Perceptions
The relevance and satisfaction with the applied early
assessment practice range from low (or not having an
approach) in two out of the three public hospitals
(H1,H2) to those stating some room for improvement
(H3,P2,P3,P6) over very useful or satisfied (P1,P4,P7,P8).
Further, no pros are mentioned by the public hospitals
while the private highlights three pros of their early
assessment practice: 1) control and standardisation
(P6,P7), 2) transparency and ease of communication
(P3,P4,P7) and 3) critical questioning and challenge of
assumptions (P1,P5,P7).
Critical questioning and control organs regarding inputs
and the process surrounding early assessments are perva-
sive in the private organisations (P1,P2,P3,P4,P5,P6,P7).
Further, there is a demand for challenge of assumptions in
about half of all the studied organisations while mainly the
public sector would like to have more structure and clear
goals. Four cons (and suggested solutions in some cases)
are mentioned by the studied organisations. First con is
more structure and clear goals/KPIs (key performance in-
dicators) (H1,H2,P2,H3). Second con is a lack of challenge
Fig. 3 Success rate: Proportion of product portfolio being commercialised/launched or achieving routine use, N = 10. Note: Each black column
represents the answer from one organisation. The grey columns are calculated averages in the public and private sector. The checkered column
is the average for all ten organisations
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of assumptions, i.e. internal and external scrutiny is neces-
sary regarding inputs in assessments. Specifically external
challenge/feedback by people without vested interests
(H3,P2,P3,P5,P7) or broader stakeholder involvement in
the form of early advisory team or workshops (H1,P8).
Third con is better needs assessment and
pre-qualification/early selection, e.g. achieved by risk
sharing (H1,H3,P3,P8). Fourth con is a need for expe-
rienced people and strategic decisions like stop/go for
IMT development made on the right organisational
level by the right people, i.e. not decided by develop-
ment or project staff (H3, P6).
Theme 5: Handling cognitive biases
This theme emerged during data analysis. A range of
statements seemed to revolve around the concept of
cognitive biases. Two cognitive biases, optimism bias
and cognitive load, and two approaches to minimise
them receive particular focus, predominately in the
private sector.
There is great understanding for the importance of
handling optimism bias (H3,P1,P2,P5,P7). Optimism bias
is sometimes countered by using historical data on prob-
ability of success, by using a devil’s advocate process to
test assumptions, by using pessimistic assumptions, etc.
The second cognitive issue may be called cognitive load.
Cognitive load refers to any demands on working mem-
ory storage and processing of information [28]. When
the load exceeds the capacity of the person processing it
causes cognitive overload. Interviews show that
gut-feelings/simple heuristics and experience play an im-
portant role in early assessments in the private sector
(P1,P3,P5,P6,P7).
Discussion
This study with interviews of 25 participants from a total
of 11 organisations investigated how early assessment is
performed in different health organisations to draw
learning points for the development of an early assess-
ment model for hospitals. The actual development and
presentation of an early assessment model for hospitals
is presented elsewhere [25]. Analysis identified four
areas where early assessment is similarly performed
across the studied organisations and four areas where
differences exists in how early assessment is performed
or perceived between public and private organisations.
The four general features across organisations regarding
how early assessment is performed are:
1. Traditional project management tools like
probability of an event multiplied by impact is
popular to assess risk or uncertainty.
2. A broad set of criteria are used and both
quantitative and qualitative methods are used to
assess them.
3. Critical questioning and challenge of assumptions
are central (and often wanted when not present),
i.e. internal and external scrutiny is necessary
regarding inputs in assessments, specifically external
feedback by people without vested interests.
4. Perceived cons are noted and include better
assessment of needs, more experienced individuals,
and strategic decisions including stop/go for IMT
development should not be decided by
development/project staff.
In four areas differences exist in how early assessment
is performed and perceived in private organisations and
public hospitals. In contrast to the situation in the pri-
vate organisations the following results were found in
the public hospitals:
5. Less or no use of: a phase model, stop/go
committees, and updates, in the developmental
process.
6. Less focus on risk assessment and handling
cognitive biases.
7. Lack of structure and clear goals/KPIs, few indicate
having an approach or template for doing early
assessments, and which attributes or effects to
include are ad-hoc.
8. Less satisfaction with current early assessments
practise. Further, no pros are mentioned which is in
contrast to private organisations highlighting three
pros of their early assessment practice: 1) control
and standardisation, 2) transparency and ease of
communication, and 3) critical questioning and
challenge of assumptions.
The above findings carry implications for early assess-
ment in hospitals. Given that hospitals list no pros and
are less satisfied with current early assessments practise
than private organisations lead us to believe that some
of the above findings present relevant learning points for
hospitals. Based in particular on bullet 7 and 8, it seems
that a more formal and critical early assessment model
is needed in hospitals rather than an ad-hoc practise
observed in this study. Thus, more in accordance with
private approaches two issues seem particular promising
when organising and performing early assessment in
hospitals. Firstly, having dedicated prioritising commit-
tees for IMTs making stop/go decisions. This committee
is separate from the IMT development processes and in-
volved staff. The committee might meet regularly, and
consist of senior management and external/internal indi-
viduals without vested interest in the IMTs. The
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committee should nurture a culture of critical question-
ing of assumptions behind the early assessments (bullet
3, 4 and 5). Secondly, supporting the committee mem-
bers in their stop/go decisions an early decision support
tool is suggested with the following five characteristics:
1) transparency, 2) a broad set of domains using both
quantitative and qualitative measures, 3) iterative, i.e.
continues measurements with a limited number of KPIs,
4) describes uncertainty, and 5) minimise cognitive
biases. The above characteristics are based in particular
on the findings in bullet 1, 2, 5, 6, 7 and 8.
Comparing results with the literature
The usefulness of iterations and frequent updates (on
KPIs) found in our study is supported by Besner and
Hobbs [29]. They find differences in level of use in
innovative and non-innovative projects regarding: up-
dated business case at gates and monitoring critical suc-
cess factors. Further, in the project management
literature it is common that the development of prod-
ucts is controlled with a phase or stage-gate model and
milestones [27], which our study confirms.
This study found some use of historical data in private
organisations, including electronic knowledge databases.
Further, stakeholder analysis and risk analysis are often
applied. These findings are supported by Besner and
Hobbs [29] identifying significant differences in the way
innovative and non-innovative projects are managed.
Based on answers from 734 mainly program directors or
project managers, they find that tools with the greatest
differences in level of use between high and low per-
formers include: 1) database for cost estimation, 2)
stakeholder analysis, 3) database of historical data,
lessons learned and risks, 4) value analysis, 5)
medium-term post evaluation of success, and 6) project
mission statement. From this study it seems that public
hospitals exhibit some of the traits of low performers,
e.g. a lack of focus on updates and risk assessment,
unclear goals, and they rarely use lessons learned from
other projects (databases of historical data). Hence,
reviewing project performance may not work well in the
public hospitals challenging the ability to perform gap
analysis, which is an important warning sign in identify-
ing low potential IMTs [30].
Our study demonstrates the importance of critical
questioning and internal and external challenge of used
assumptions in the early assessment. Ballini et al. [31]
used a multidisciplinary panel inviting “sceptics” to con-
tribute to the early assessment process. Bonabeau,
Bodick and Armstrong [32] recommends a segmented
approach to new product development with two phases:
“an early stage that focuses on evaluating prospects and
eliminating bad bets, and a late stage that maximises the
remaining candidates’ market potential”. In this
approach, the early-stage organisation maintains loyalty
to the experiment rather than to the product. Hence,
both studies underline that you cannot objectively re-
view your own product but need assistance.
In our study, the reported average success rate is 10%
across organisations (15% in the public vs. 8% in the pri-
vate). However, stating a success rate is not trivial and
depends on many factors. One factor influencing the
success rate is what kind of technologies the organisa-
tions have chosen to include when answering the ques-
tions. It is likely that the IMTs in the public sector are
more mature on average compared to the private IMTs
and as a consequence they have a higher success rate.
Other differences in IMT characteristics include the
development period for the included IMTs, which varies
a lot. In the literature, success rates, i.e. the probability
of commercial success rate, for early stage private ven-
tures are reported to be on average 11% [33]. In pharma-
ceuticals, where the lead time can easily reach 15 years,
there is an overall success rate of only 0.002% and the
company tracks the success rate and duration in every
phase from discovery to marketing approval [30].
This study identified two cognitive biases and the
importance of actively handling these. Cook [34] handles
the topic of overconfidence in judgmental forecasting
and lists six principles that forecasters should heed in
order to counteract overconfidence. Our findings are
consistent with several of these principles underlining
the importance of tackling overconfidence, i.e. optimism
bias, in early assessment.
Strengths and limitations of this study
This study is to our knowledge the first to explore how
early assessment is carried out in different health organi-
sations, with the aim of identifying leaning points for
hospitals. The study constituted the basis for and partly
guided data extraction in a literature review of early
assessment [22] and might inform further studies in the
field. As the study is exploratory and restricted to a
Danish context the ability to generalise the findings is
somewhat limited. Other limitations include a decision
for interviews to be confidential and not tape recorded
which was deemed necessary to gain access to key per-
sons in a competitive and secretive area. However, this
choice was based on literature and without in practice
investigating whether resistance was present towards
recording and transcribing the interviews. In retrospect
this ought to have been explored explicitly.
Participants were deliberately chosen to reflect a high
level of variation adhering to the principle of maximum
variation where the researcher selects a small number of
cases that maximize the diversity relevant to the
research question [35]. The interviewed organisations
matched the goal of large variation, both regarding
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number of products in pipeline, time horizon in product
development, success rate, and experience with early
assessments including position of participants in the
organisations.
Large organisations in the pharmaceutical industry,
medical device industry, and public hospitals were pre-
ferred for inclusion since more sophisticated or
cutting-edge methods might be more likely found in lar-
ger organisations with distinct departments for research
portfolio analysis and planning. The included private
sector organisations were chosen because of extensive
experience regarding R&D investments. An annual
Industrial R&D Investment Scoreboard published by the
European Commission [36] shows that the pharmaceuti-
cals & biotechnology sector is leading in R&D invest-
ments and therefore may be assumed to be skilled to
make early assessments regarding R&D investments.
However, the possibility exists that including for
example small companies, experience from venture capi-
talists, or “incubator helpers”, could have provided valu-
able input. Venture capitalists are considered experts in
identifying high-potential IMTs and their ventures sur-
vive at a much higher rate than ventures backed by other
sources [37].
Transferability of results and future research
Transferring results from private sector approaches to a
hospital context requires adaptations to be relevant for
the hospitals’ decision problem. First, the criterion for
decision making may be different, e.g. commercial
potential and profitability vs. clinical potential, benefit to
patients, and costs. Also, the time horizon in product
development differs in the included sectors. Further, in
the private sector, IMT development (innovation) is the
cornerstone of the business in contrast to the public
hospitals where this activity naturally is secondary to the
main task of delivering established healthcare services.
Given the above differences, the more formal (or profes-
sional) practice observed in the private sector regarding
early assessment is not surprising. However, since
resources spent on innovation (IMTs and projects) are
rising in the public sector, we believe that the private
sector approaches is increasingly relevant for a public
context. Further, the included sectors are familiar with
clinical effects and often also the cost-effectiveness con-
cept, which is considered positive for transferability of
results to a hospital context.
The context theme seemed to indicate a possible dif-
ference in experience level between hospitals and private
companies. Thus, a direct question on number of years
employed with early assessing IMTs would have been
relevant to include. With such information an experi-
ence ordered matrix could have been constructed which
may have yielded interesting analysis results. Moreover,
it may be interesting to explore the higher self-reported
success rates in public hospitals compared to the private
organisations. The concept of a success rate was well
known and used in private organisations and they often
had a straight answer and a practice of tracking this
measure. Public hospitals needed more explanation and
the concept seemed less familiar and used. We believe it
relevant with future research into whether possible dif-
ferences exist in how the success rate is perceived and
used in the two sectors. Also, more efforts could have
been directed on how the different organisations might
have different requirement and concerns at different
stages of technology development from early stages and
onwards. Finally, an open question on how early assess-
ment is defined in each of the interviewed organisation
would have been relevant.
Conclusions
In this study similarities and differences in the way early
assessment is done in different health organisations was
identified. Based on this, two learning points in particu-
lar seemed relevant for hospitals. Firstly, having dedi-
cated prioritising committees for IMTs making stop/go
decisions. This committee is separate from the IMT
development processes and involved staff. Secondly, the
committee should base decisions on a decision-support
tool with five characteristics (transparency, a broad set
of domains, iterative, describes uncertainty, and minim-
ise cognitive biases). Thus, findings from this explorative
study are believed to carry promising elements for the
development of an early assessment model adapted to
hospitals.
Additional file
Additional file 1: A conceptual framework for design of the interview
study and statements from the response data supporting the results of
each theme are presented. (DOCX 32 kb)
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